Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders

Peptides

Volumn 22, Issue 5, 2001, Pages 835-844

  Keck, Martin E ^a   Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Antidepressant; Anxiety; Corticotropin releasing factor; Corticotropin releasing hormone; Corticotropin releasing hormone receptor antagonist; Depression; Hypothalamic pituitary adrenocortical (HPA) system; Stress

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANXIOLYTIC AGENT; BENZODIAZEPINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXAMETHASONE; DIAZEPAM; IODINE 125; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TETRAHYDRODEOXYCORTICOSTERONE; TETRAHYDROPROGESTERONE; UNCLASSIFIED DRUG;

AFFECTIVE NEUROSIS; ANXIETY NEUROSIS; ARTICLE; BEHAVIOR; BRAIN NERVE CELL; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG TARGETING; ENVIRONMENTAL FACTOR; GENE TARGETING; HEREDITY; HORMONAL REGULATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NERVE CELL NETWORK; NEUROANATOMY; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT STRAIN; SLEEP DISORDER; STRESS; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; CORTICOTROPIN-RELEASING HORMONE; DISEASE MODELS, ANIMAL; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MICE; MICE, TRANSGENIC; MOOD DISORDERS; NEURONS; OLIGORIBONUCLEOTIDES, ANTISENSE; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS;

EID: 0035040487     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(01)00398-9     Document Type: Article

References (101)

1. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age
2. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress
3. Endocrine profile and neuroendocrine challenge test in transgenic mice expressing antisense RNA against the glucocorticoid receptor
4. Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease
5. Regulation of the messenger ribonucleic acid for corticotropin-releasing factor in the paraventricular nucleus and other brain sites of the rat
6. Disease, distress and depression. A comment
7. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 receptor mRNA expression
8. Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult non-human primates exposed to early-life stressors: Implications for the pathophysiology of mood and anxiety disorders
9. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2
10. Prenatal stress enhances stress- and corticotropin-releasing factor-induced stimulation of hippocampal acetylcholine release in adult rats
11. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression
12. Brain corticosteroid receptor balance in health and disease
13. Reduced activity of hypothalamic corticotropin-releasing hormone neurons in transgenic mice with impaired glucorticoid receptor function
14. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression
15. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans
16. Animal models of psychiatric disorders
17. Characterization of corticotropin-releasing factor receptor subtypes
18. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior
19. Unconditioned anxiety and social behaviour in two rat lines selectively bred for high and low anxiety-related behaviour
20. The combined dexamethasone CRH test - A refined laboratory test for psychiatric disorders
21. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and in normal comparison subjects
22. Neuroendocrinology of mood disorders
23. Animal models of mood disorders
24. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety
25. The corticosteroid receptor hypothesis of depression
26. Antidepressants and hypothalamic-pituitary-adrenocortical regulation
27. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders
28. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia
29. Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man
30. Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment - Neurobiological and psychometric assessment of course
31. Hypothalamic-pituitary-adrenocortical axis changes in a transgenic mouse with impaired glucocorticoid receptor function
32. Repetitive transcranial magnetic stimulation induces active coping strategies and attenuates the neuroendocrine stress response in rats
33. Ageing alters intrahypothalamic release patterns of vasopressin and oxytocin in rats
34. Neuroendocrine and behavioral effects of repetitive transcranial magnetic stimulation in a psychopathological animal model are suggestive of antidepressant-like effects
35. 1 receptor antagonist R121919 depends on innate emotionality in rats
36. The combined Dex/CRH-test in high anxiety rats: Involvement of endogenous vasopressin
37. Major depression and the environment: A psychiatric genetic perspective
38. Stressful life events and genetic liability to major depression: Genetic control of exposure to the environment?
39. Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2
40. 2γ receptor
41. Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation
42. Anxiety-related effects in the sleep response to stress are mediated by the hypothalamo-pituitary-adrenal (HPA) axis and attenuated by R121919
43. Hyperreactive hypothalamo-pituitary-adrenocortical (HPA) axis in rats bred for high anxiety-related behavior
44. Neuroendocrine and behavioral effects of antisense oligonucleotides
45. The Munich vulnerability study on affective disorders: Overview of the cross-sectional observations at index investigation
46. Corticotropin-releasing hormone-mediated neuroprotection against oxidative stress is associated with the increased release of non-amyloidogenic amyloid β precursor protein and with the suppression of nuclear factor-κB
47. Differential behavioural effects of chronic infusion of CRH1 and CRH2 receptor antisense oligonucleotides into the rat brain
48. 1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats
49. Behavioral, physiological, and neuroendocrine stress responses and differential sensitivity to diazepam in two Wistar rat lines selectively bred for high and low anxiety-related behavior
50. Behavioural profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour
51. Glucocorticoid receptor impairment alters CNS responses to a psychological stressor: An in vivo microdialysis study in transgenic mice
52. Long-term intracerebroventricular infusion of corticotropin-releasing hormone alters neuroendocrine, neurochemical, autonomic, behavioral, and cytokine responses to a systemic inflammatory challenge
53. Regulation of serotonin 1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: Implications for the neurobiology of depression
54. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain
55. Effects of corticosterone on CRH mRNA and content in the bed nucleus of the stria terminalis; comparison with the effects in the central nucleus of the amygdala and the paraventricular nucleus of the hypothalamus
56. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders
57. Corticosteroid receptor function is decreased in depressed patients
58. Long-term antidepressant treatment reduces behavioral deficits in transgenic mice with impaired glucocorticoid receptor function
59. Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids
60. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims
61. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients
62. Antisense oligodeoxynucleotides in neuroendocrinology: Enthusiasm and frustration
63. Increased basal activity of the hypothalamo-pituitary-adrenal axis during pregnancy in rats bred for high anxiety-related behaviour
64. Maternal deprivation affects behaviour from youth to senescence: Amplification of individual differences in spatial learning and memory in senescent Brown Norway rats
65. Physiology and pharmacology of corticotropin-releasing factor
66. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events
67. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin releasing hormone in the rat hypothalamus
68. Neuroactive steroids
69. Life events and depression. A controlled study
70. Impaired type II glucocorticoid receptor function in mice bearing antisense RNA transgene
71. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor
72. Identifcation of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart
73. Early postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats
74. Region-specific alterations in corticotropin releasing factor (CRF) mRNA distribution and CRF-R2 binding in rats bred for high anxiety-related behavior (HAB)
75. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain
76. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression
77. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular of depressed patients
78. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide
79. Altered neuroimmunoendocrine communication during a condition of chronically increased brain corticotropin-releasing hormone drive
80. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system
81. Prenatal immune challenge alters the hypothalamic-pituitary-adrenocortical axis in adult rats
82. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives
83. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness
84. Induction of corticotropin-releasing hormone gene expression by glucocorticoids: Implication for understanding the states of fear and anxiety and allostatic load
85. Enhanced morphine-induced behavioural effects and dopamine release in the nucleus accumbens in a transgenic mouse model of impaired glucocorticoid (type II) receptor function: Influence of long-term treatment with the antidepressant moclobemide
86. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats
87. Antisense oligodeoxynucleotide complementary to corticotropin-releasing hormone mRNA reduces anxiety in shuttle-box performance
88. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety
89. Corticotropin-releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development
90. Dexamethasone nonsuppression in transgenic mice expressing antisense RNA to the glucocorticoid receptor
91. Corticotropin-releasing hormone receptor subtypes and emotion
92. Glucocorticoid receptor impairment enhances impulsive responding in transgenic mice performing on a simultaneous visual discrimination task
93. Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery
94. Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: A hybridization histochemical study in the rat
95. Phenotypic plasticity of CRF neurons during stress
96. Mice lacking a functional corticotropin-releasing hormone receptor 1 show impaired stress response and reduced anxiety under basal and alcohol withdrawal conditions
97. Periodic maternal deprivation induces gender-dependent alterations in behavioral and neuroendocrine responses to emotional stress in adult rats
98. Animal models of depression: Validity and applications
99. Chronic mild stress-induced anhedonia: A realistic animal model of depression
100. Effects of the high affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients
101. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression